Parent Drug and Active Metabolite (FDA) [Regulatives / Guidelines]

posted by joyjac – Philippines, 2006-05-10 07:44 (6617 d 12:19 ago) – Posting: # 122
Views: 8,257

Dear HS,

Just to clarify in case of (2): 90% CI will be applied to the parent drug and present the metabolite data descriptively - would this mean that ANOVA on the metabolite data is not necessary?

Thanks for sharing your expertise.

Complete thread:

UA Flag
 Admin contact
23,059 posts in 4,841 threads, 1,664 registered users;
36 visitors (0 registered, 36 guests [including 5 identified bots]).
Forum time: 20:03 CEST (Europe/Vienna)

[…] an inappropriate study design is incapable of answering
a research question, no matter how careful the subsequent
methodology, conduct, analysis, and interpretation:
Flawless execution of a flawed design achieves nothing worthwhile.    J. Rick Turner

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz